Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05071274 · ClinicalTrials.gov registry record · NA

A Proof of Concept Study to Evaluate the Efficacy and Tolerability of Microneedling With SkinPen in Female and Male Subjects With Facial Acne Vulgaris, Ages 18 Through 45

A NA study, sponsored by Crown Laboratories.

Completed
Registry status
NA
Development phase
31
Enrollment target

NCT05071274: Completed NA study, sponsored by Crown Laboratories.

NCT05071274 is a NA study that has completed, run by Crown Laboratories. The registered enrollment target is 31 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05071274, a NA study, has completed, sponsored by Crown Laboratories.

COMPLETED
Registry status
NA
Development phase
31 participants
Enrollment target

Study Summary

This single-center, proof of concept trial is being conducted over the course of 42 days followed by a 2-month post-last treatment visit in order to assess the efficacy and tolerability of the Sponsor's SkinPen device in treating Acne Vulgaris on the face.

Primary Outcome

The primary endpoint of the study is reduction of lesion count from Visit 1 (baseline) to Visit 5, in the inflammatory (papules and pustules) and non-inflammatory (open and closed comedones) lesions.

Interventions

  • DEVICE Skinpen Prescision System

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2021-03-15
Est. Completion 2022-03-18
Phase NA
Crown Laboratories

4 total trials

What the finished NCT05071274 record still lists

NCT05071274 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 1 intervention - of which Skinpen Prescision System is the first listed.

NCT05071274 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05071274 about?

NCT05071274 is a clinical study titled "A Proof of Concept Study to Evaluate the Efficacy and Tolerability of Microneedling With SkinPen in Female and Male Subjects With Facial Acne Vulgaris, Ages 18 Through 45". This single-center, proof of concept trial is being conducted over the course of 42 days followed by a 2-month post-last treatment visit in order to assess the efficacy and tolerability of the Sponsor's SkinPen device in treating Acne Vulgaris on the face.

What is the current status of trial NCT05071274?

This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2021-03-15. Estimated completion is 2022-03-18.

What interventions are being tested in trial NCT05071274?

The interventions under investigation include: Skinpen Prescision System (DEVICE).

Who is sponsoring clinical trial NCT05071274?

This trial is sponsored by Crown Laboratories, which has 4 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05071274's enrollment target sits among peer trials

31 1592nd of 2000 higher than 408 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02932618 · 31 participants · Phase 3

    A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

  • NCT03482297 · 31 participants · Phase 1

    Automated Abdominal Binder for Orthostatic Hypotension

  • NCT04016389 · 31 participants · NA

    FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery

  • NCT04211675 · 31 participants · Phase 1

    NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05071274, the US trial registry maintained by the National Library of Medicine. NCT05071274 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.